Hepion Pharmaceuticals Inc.
08/07/2024 | Press release | Distributed by Public on 08/07/2024 07:09
Management Change/Compensation - Form 425
| Item 5.02 | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
On August 5, 2024, John Cavan, the interim Chief Executive Officer and Chief Financial Officer of Hepion Pharmaceuticals, Inc. (the "Company") left the Company for personal reasons. On August 6, 2024, John Brancaccio, the Company's executive chairman was appointed the interim Chief Executive Officer and interim Chief Financial Officer of the Company.